MedTrace Logo

Apremilast in Psoriatic Arthritis in Real-life Clinical Practice in Greece

NCT03780504 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2021-12-21

No results posted yet for this study

Summary

Following the evidence from the controlled clinical trial setting on the significant clinical benefits of apremilast in the treatment of active PsA, there is a scarcity of real-life evidence on the effectiveness and the beneficial role of apremilast in PsA in routine clinical practice. The present study primarily aims to generate real-world evidence on the impact of apremilast treatment on a broad population of biologic-naïve PsA patients in terms of its clinical effectiveness across the wide spectrum of disease manifestations, as well as its impact on disease burden and HRQoL, in the routine primary care settings of Greece.

Conditions

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • Genesis Pharma S.A.

    lead INDUSTRY

Principal Investigators

  • Nikos Antonakopoulos, MD · Genesis Pharma S.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2021-07-20
Completion
2022-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03780504 on ClinicalTrials.gov